Drug Profile
Research programme: cancer immunotherapies - Forbius
Latest Information Update: 26 Apr 2023
Price :
$50
*
At a glance
- Originator AvidBiologics
- Developer Forbius; National Research Council Canada
- Class Antibodies; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Epidermal growth factor receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Head and neck cancer; Solid tumours
Most Recent Events
- 21 Mar 2023 Discontinued - Preclinical for Breast cancer in Canada (Parenteral)
- 21 Mar 2023 Discontinued - Preclinical for Head and neck cancer in Canada (Parenteral)
- 21 Mar 2023 Discontinued - Preclinical for Solid tumours in Canada (Parenteral)